Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 16/20 | 0.41 |
| ▸ | QPCT | Q16769 | 2/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908818 | 0.89 | MAPKAPK2 (0.42) | MAPKAPK2CXCR2QPCTCYP2C9PDGFRA | |
| SCHEMBL4906078 | 0.89 | MAPKAPK2 (0.47) | MAPKAPK2CXCR2QPCTCXCR1ROCK1 | |
| SCHEMBL4597016 | 0.89 | MAPKAPK2 (0.47) | MAPKAPK2CXCR2QPCTCXCR1ROCK1 | |
| SCHEMBL4910847 | 0.88 | MAPKAPK2 (0.42) | MAPKAPK2CXCR2QPCTCXCR1CYP2C9 | |
| SCHEMBL4906181 | 0.88 | MAPKAPK2 (0.40) | MAPKAPK2CXCR2QPCTCXCR1CYP2C9 | |
| SCHEMBL4596962 | 0.87 | MAPKAPK2 (0.61) | MAPKAPK2CYP2C9PDGFRAPRKCAMAPK1 | |
| SCHEMBL4598811 | 0.87 | MAPKAPK2 (0.61) | MAPKAPK2CYP2C9PDGFRAPRKCAMAPK1 | |
| SCHEMBL4598110 | 0.86 | MAPKAPK2 (0.49) | MAPKAPK2CYP2C9PDGFRAPRKCAMAPK1 | |
| SCHEMBL14066740 | 0.83 | MAPKAPK2 (0.38) | MAPKAPK2CXCR2CXCR1CYP2C9PDGFRA | |
| SCHEMBL14066741 | 0.83 | HPGD (0.38) | MAPKAPK2CXCR2CYP2C9PDGFRAPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234266-A1 | Squaric Acid Derivatives II | MERCK PATENT GESELLSCHAFT (DE) | 2008-09-25 | — | — | US | claimed |
| EP-1910312-A1 | QUADRATIC ACID II DERIVATIVES | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007014608-A1 | QUADRATIC ACID II DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234266-A1 | Squaric Acid Derivatives II | CHEK2, CHEK1, SGK3 | MAPKAPK2 346/4885CXCR2 1478/4885QPCT 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.